封面
市場調查報告書
商品編碼
1086075

泛自閉症障礙 (ASD) 治療藥的市場規模、佔有率、展望、機會 (2022年~2028年):各藥物類型、年齡層、流通管道、地區

Autism Spectrum Disorder Therapeutics Market, by Drug Type, by Age Group, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 308 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

泛自閉症障礙 (ASD) 的盛行率的全球增加支援泛自閉症障礙 (ASD) 治療藥市場成長。預計同時,銷售相關嚴格法規,持續性監視成為醫藥品的認證該市場的成長的潛在的障礙。

本報告提供全球泛自閉症障礙 (ASD) 治療藥的市場調查,市場定義和概要,市場成長的各種影響因素分析,法律規章、償付情境,開發平台的分析,市場規模的變化、預測,各種區分、各地區/主要國家的明細,競爭環境,主要企業簡介等彙整。

目錄

第1章 調查目的、前提條件

第2章 市場概要

第3章 市場動態、法律規章、趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 市場趨勢
  • 主要的發展
  • 法規情形
  • 聯盟、合作
  • 流行病學分析
  • 開發平台分析、核准產品的分析
  • 法規情境
  • 償付情境
  • 波特的五力分析

第4章 全球泛自閉症障礙 (ASD) 治療藥市場:各藥物類型

  • Aripiprazole
  • Risperidone
  • 褪黑激素
  • CM-AT
  • Bumetanide
  • Balovaptan

第5章 全球泛自閉症障礙 (ASD) 治療藥市場:各年齡層

  • 幼兒
  • 成人

第6章 全球泛自閉症障礙 (ASD) 治療藥市場:各流通管道

  • 醫院藥局
  • 零售藥局
  • 線上藥局

第7章 全球泛自閉症障礙 (ASD) 治療藥市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第8章 競爭情形

  • 企業簡介
    • F. Hoffmann-La Roche AG
    • Neurim Pharmaceuticals, Inc.
    • Yamo Pharmaceuticals LLC
    • Servier Laboratories Ltd.
    • Otsuka Holdings Co. Ltd.
    • Curemark LLC
    • Oryzon Genomics SA
    • GW Pharmaceuticals Plc.
    • Teva Pharmaceutical Industries Ltd.
    • Zynerba Pharmaceuticals Inc.
    • STALICLA SA
    • Novartis AG
    • Pfizer, Inc.
    • Bristol Myers Squibb
  • 分析師的見解

第9章 Section

簡介目錄
Product Code: CMI2643

Autism, scientifically referred as Autism Spectrum Disorder Therapeutics (ASD) is a complex neurological disorder that is characterized by symptoms including challenges with social skills, repetitive behaviours, as well as issues with speech and non-verbal communication. Major companies operating in the ASD therapeutics market are focusing on extensive research & development and clinical trials to introduce new drugs. For instance, in February 2019, Servier Laboratories Ltd. and Neurochlore announced the launch of phase 3 studies to evaluate the use of Bumetanide in children with ASD. Bumetanide is typically used to treat fluid retention (edema) and high blood pressure.

Market Dynamics

Increasing prevalence of ASD worldwide is expected to boost the Autism Spectrum Disorder Therapeutics (ASD) therapeutics market growth. For instance, according to the data published in Our World in Data in 2017, around 62 million people worldwide were estimated to have ASD in 2016. Moreover, under 50 million of these cases were found in males. Of this 62 million with ASD, around 18 million had only Autism and 44 million had Asperger syndrome and other spectrum disorders.

However, stringent regulations and continuous watch employed by governing authorities for product approval and marketing of medicines can act as a potential hindrance for growth of the autism spectrum disorder therapeutics market. For instance, in May 2017, the U.S. Food and Drug Administration (FDA) shut down operations of Louisiana-based Pick and Pay Inc. Cili Minerals, a manufacturer of drug and dietary supplements, after finding that the company was falsely marketing products as being able to treat autism.

Key features of the study:

This report provides in-depth analysis of the autism spectrum disorder therapeutics market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022 - 2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autism spectrum disorder therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include, F. Hoffmann-La Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol Myers Squibb

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global autism spectrum disorder therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for Autism Spectrum Disorder Therapeutics market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Autism Spectrum Disorder Therapeutics Market, By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

Global Autism Spectrum Disorder Therapeutics Market, By Age Group:

Child

Adult

Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Autism Spectrum Disorder Therapeutics Market, By Region:

North America

By Country:

U.S.

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Canada

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Europe

By Country:

U.K.

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Germany

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Italy

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Spain

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

France

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Russia

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Europe

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Asia Pacific

By Country:

China

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Japan

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

India

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

ASEAN

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Australia

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

South Korea

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Asia Pacific

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Latin America

By Country:

Brazil

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Mexico

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Argentina

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Latin America

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Middle East

By Country:

GCC

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Israel

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Rest of Middle East

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Africa

By Country/Region:

South Africa

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Central Africa

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

North Africa

By Drug Type:

Aripiprazole

Risperidone

Melatonin

CM-AT

Bumetanide

Balovaptan

By Age Group:

Child

Adult

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Company Profiles

F. Hoffmann-La Roche AG.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Neurim Pharmaceuticals, Inc.

Yamo Pharmaceuticals LLC

Servier Laboratories Ltd.

Otsuka Holdings Co. Ltd.

Curemark LLC

Oryzon Genomics S.A.

GW Pharmaceuticals Plc.

Teva Pharmaceutical Industries Ltd.

Zynerba Pharmaceuticals Inc.

Stalicla SA.

Novartis AG

Pfizer, Inc.

Bristol Myers Squibb.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Age Group
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Landscape
  • Collaborations & Partnerships
  • Epidemiology Analysis
  • Pipeline Analysis & Approved Product Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • Porter's Five Forces model

4. Global Autism Spectrum Disorder Therapeutics Market, By Drug Type, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Aripiprazole
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Risperidone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Melatonin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • CM-AT
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Bumetanide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Balovaptan
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Autism Spectrum Disorder Therapeutics Market, By Age Group, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Child
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Autism Spectrum Disorder Therapeutics Market, By Distribution Channel, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Autism Spectrum Disorder Therapeutics Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Age Group, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Neurim Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Yamo Pharmaceuticals LLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Servier Laboratories Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Otsuka Holdings Co. Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Curemark LLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Oryzon Genomics S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GW Pharmaceuticals Plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Zynerba Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • STALICLA SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol Myers Squibb
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact